Targeted Monoclonal Antibody Therapy in Cancer

Medicines prepared to intervene with the molecular target, which is thought to be an important effect on tumor growth and progression, constitute the basis of targeted treatment. The cancer mechanism needs to be well understood in order to determine the correct treatment and target. Targeted therapy is a type of treatment that targets defective genes, proteins, or tissue media that contribute to cancer growth and development. These therapies include signal transduction inhibitors, immunotherapies, and hormone therapies. Treatment with monoclonal antibodies is one of the targeted therapeutic options and demonstrates anti-tumor effects by receptor signaling to which IgG antibodies are linked, cell-mediated cytotoxicity and complement-dependent cytotoxic effects. In this review, the structure, function, and mechanism of action of targeted monoclonal antibodies in targeted cancer therapy will be examined.

[1]  J. Ficker,et al.  Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice – results from the ElderTac study , 2018, BMC Cancer.

[2]  Z. Dai,et al.  Recent advances in anti-angiogenic nanomedicines for cancer therapy. , 2018, Nanoscale.

[3]  N. Agarwal,et al.  Bone-targeted therapies to reduce skeletal morbidity in prostate cancer , 2018, Asian journal of andrology.

[4]  A. Choo,et al.  Targeting of embryonic annexin A2 expressed on ovarian and breast cancer by the novel monoclonal antibody 2448 , 2018, Oncotarget.

[5]  U. Wollina,et al.  Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer , 2017, Open access Macedonian journal of medical sciences.

[6]  Debarshi Kar Mahapatra,et al.  K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives. , 2017, European journal of medicinal chemistry.

[7]  Paul Polakis,et al.  Site-specific antibody drug conjugates for cancer therapy , 2013, mAbs.

[8]  Wen-chao Song,et al.  Complement and its role in innate and adaptive immune responses , 2010, Cell Research.

[9]  F. Zhan,et al.  Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma , 2009, Molecular Cancer Therapeutics.

[10]  R. Noelle,et al.  Molecular mechanism and function of CD40/CD40L engagement in the immune system , 2009, Immunological reviews.

[11]  N. Munshi,et al.  Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. , 2008, Blood.

[12]  F. Zhan,et al.  CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma , 2008, Clinical Cancer Research.

[13]  J. Schellens,et al.  Development of farnesyl transferase inhibitors: a review. , 2005, The oncologist.

[14]  G. Adams,et al.  Monoclonal antibody therapy of cancer , 1999, Nature Biotechnology.

[15]  S. Quezada,et al.  CD40/CD154 interactions at the interface of tolerance and immunity. , 2004, Annual review of immunology.

[16]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.